FDA approves Viridian's Lumvoa for thyroid eye disease in both active and chronic disease
Veligrotug produced a proptosis response in 70% of patients with active disease and 57% with chronic disease at week 15.
Belite Bio Announces Registered Direct Offering of $15 Million
✨ Onyx Summary Belite Bio entered a registered direct offering with a single large existing institutional shareholder to sell 230,770 ADSs and accompanying five-year warrants for another 230,770 ADSs at $65 per unit, for gross proceeds of about $15M (with up to an additional ~$15M possible upon warrant